Baricitinib is an oral prescription medicine belonging to the Janus kinase inhibitor class. It primarily inhibits JAK1 and JAK2 and modifies immune and inflammatory signaling.

Its approved uses depend on the country. Current U.S. labeling includes specified uses in rheumatoid arthritis, severe alopecia areata and hospitalized adults with COVID-19 requiring specified respiratory support. European authorization also includes atopic dermatitis and selected juvenile idiopathic arthritis.

Baricitinib modifies immune signaling and can reduce immune-system activity. Because of this pharmacologic effect, patients may have an increased risk of infections.

Baricitinib is a Janus kinase inhibitor, or JAK inhibitor. It is an oral prescription medicine that primarily targets JAK1 and JAK2 signaling pathways involved in immune and inflammatory responses.

Baricitinib primarily inhibits JAK1 and JAK2. By interfering with these signaling enzymes, it can reduce signaling from certain cytokines involved in immune and inflammatory processes.

Barinib 2 mg is one of the products identified in the supplied website brief as containing baricitinib at a 2 mg strength. Patients should verify the active ingredient, strength, packaging and manufacturer information on the actual product before use.

Barigen 4 mg is identified in the supplied website brief as a 4 mg baricitinib product. The appropriate dose depends on the indication, patient characteristics and prescribing instructions from a qualified healthcare professional.

The supplied website brief lists the company for both Barinib and Barigen as General. No more specific manufacturer should be claimed without reliable product documentation.

Baricitinib is not conventional cytotoxic chemotherapy. It is a targeted immunomodulatory medicine classified as a Janus kinase inhibitor and is used in specific immune-mediated and inflammatory conditions according to applicable approvals.

Baricitinib inhibits JAK1 and JAK2, reducing signaling from cytokines involved in immune and inflammatory processes. This action can help modify excessive immune activity in conditions for which baricitinib is prescribed.

Depending on the indication, baricitinib is generally administered once daily. The exact dose and regimen must be prescribed by a healthcare professional based on the condition being treated, age, kidney function and other relevant factors.

Current U.S. product information allows baricitinib to be taken with or without food. Patients should follow the instructions provided with their specific product and prescription.

Do not automatically double the next dose. Follow the specific missed-dose instructions provided with the medicine or ask a pharmacist or healthcare professional for advice based on your prescribed regimen.

Yes. Serious infections are an important safety concern with baricitinib. Tuberculosis and other bacterial, fungal and viral infections may occur because the medicine modifies immune-system activity. Seek medical attention for signs of a serious infection.

Thrombosis is an important recognized risk associated with JAK inhibitors, including baricitinib. Patients should promptly seek medical assessment for symptoms that could indicate a blood clot, such as unexplained swelling or pain in an extremity or sudden chest discomfort or breathing difficulty.

Changes in lipid parameters can occur during treatment with baricitinib. Lipid monitoring may therefore be appropriate according to the prescribing information and the patient's individual medical circumstances.

Pregnancy requires careful consideration. Current European product information states that baricitinib should not be used during pregnancy. Patients who are pregnant, planning pregnancy or who could become pregnant should discuss treatment with their healthcare professional.

Current U.S. labeling advises against breastfeeding during treatment with baricitinib and for four days after the last dose. Patients who are breastfeeding or planning to breastfeed should discuss treatment options with their healthcare professional.

Yes. Concomitant immunosuppressive medicines and other drugs can affect treatment decisions. A complete medication list should be reviewed by the treating professional, including prescription medicines, over-the-counter products, vitamins and supplements.

Suitability depends on the indication and patient characteristics. Particular caution is required with serious infections, tuberculosis, significant blood-count abnormalities, renal impairment, pregnancy and certain cardiovascular or thrombotic risk factors. A healthcare professional should determine whether treatment is appropriate.

Patients should not stop prescribed baricitinib independently. Treatment interruption may sometimes be medically appropriate, particularly in certain safety situations, but the decision should be made by the treating healthcare professional.

Follow the storage instructions printed on the specific product packaging and official product information. Keep the medicine in its original packaging when appropriate and store it away from conditions that could damage the product.

This depends on the jurisdiction and indication. European authorization includes specified uses in children and adolescents, including atopic dermatitis from age 2 and severe alopecia areata from age 12. Pediatric use should always follow the applicable local product information and specialist medical guidance.

A 4 mg tablet contains twice as much active ingredient as a 2 mg tablet, but “stronger” does not mean medically better. The appropriate dose depends on the disease, treatment goal, kidney function, age and other patient-specific factors. Do not change between strengths without medical advice.